1. Regelson W, Holland JF, Frei E III, Gold GL, Hall TC, Krant M, Miller SO (1964) Comparative clinical toxicity of 6-mercaptopurine (NSC-755) and 6-mercaptopurine ribonucleoside (NSC-4911) administered intravenously to patients with advanced cancer. Cancer Chemother Rep 36: 41–48
2. Regelson W, Holland JF, Gold GL, Lynch J, Olson KB, Horton J, Hall TC, Krant M, Colsky J, Miller SP, Owens A (1967) 6-Mercaptopurine (NSC-755) given at weekly intervals to patients with advanced cancer. Cancer Chemother Rep 51: 277–282
3. Tidd DM, Paterson ARP (1974) A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34: 738–746
4. Zimm S, Collins JM, Riccardi R, O’Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308: 1005–1009
5. Zimm S, Ettinger LJ, Holcenberg JS, Kamen BA, Vitti TJ, Belasco J, Cogliano N, Balis FM, Lavi LE, Collins JM, Poplack DG (1985) Phase I and clinical pharmacological study of 6-mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45: 1869–1873